CAR T cells in multiple myeloma: Where we stand and where we might be going
Authors:
- 17 August 2022
- journal article
- review article
- Published by Springer Nature in memo - Magazine of European Medical Oncology
- Vol. 15 (3) , 1-5
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myelomaNature Communications, 2020
- Engineering strategies to overcome the current roadblocks in CAR T cell therapyNature Reviews Clinical Oncology, 2019
- γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myelomaBlood, 2019
- The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cellsScience Translational Medicine, 2019
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2019
- Transfection of chimeric anti‐CD138 gene enhances natural killer cell activation and killing of multiple myeloma cellsMolecular Oncology, 2013
- PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy ResponsesScience Translational Medicine, 2013
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myelomaLeukemia, 2013
- Overexpression of G protein‐coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myelomaEuropean Journal of Clinical Investigation, 2012
- HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cellsBlood, 2005